Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

NCT03310632 is registered in ClinicalTrials.gov with Golden Biotechnology Corporation as lead sponsor.

NCT NCT03310632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03310632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Lead sponsor
Golden Biotechnology Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2017
Completion date
January 2, 2024
Enrollment
55 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasm